Below is Validea's guru fundamental report for TWIST BIOSCIENCE CORP (TWST). Of the 22 guru strategies we follow, TWST rates highest using our P/B Growth Investor model based on the published ...

Twist Bioscience Corp (NASDAQ:TWST) reported record revenue of $88.7 million for the first quarter of 2025, marking a 24% year-over-year increase. The company achieved a gross margin of 48.3% ...

Twist Bioscience (TWST) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.75 per share a year ago. These figures ...

Barclays analyst Luke Sergott maintained a Buy rating on Twist Bioscience (TWST – Research Report) today and set a price target of $52.00. The company’s shares closed last Friday at $52.37.

Twist Bioscience (NASDAQ:TWST) report strong results in the first quarter of FY25, driven by its SynBio and NGS segments. While Twist's core businesses continue to thrive in a tough macro ...

TWST stock opened at $53.70 on Thursday. The stock has a fifty day moving average of $48.84 and a 200-day moving average of $46.32. Twist Bioscience has a fifty-two week low of $27.41 and a fifty ...

Twist Bioscience (TWST) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

In this article, we are going to take a look at where Twist Bioscience Corporation (NASDAQ:TWST) stands against the other stocks in Cathie Wood’s portfolio. Cathie Wood is one of Wall Street’s ...

Good day. Thank you for standing by. Welcome to Twist Bioscience's 2025 First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the ...

Scotiabank raised the firm’s price target on Twist Bioscience (TWST) to $62 from $54 and keeps an Outperform rating on the shares. The company’s Q1 results beat consensus and guidance ...